Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy

ABSTRACT Background Outcomes for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that have progression after treatment with hypomethylating agent (HMA) and venetoclax (VEN) are poor. However, data for chemotherapy and VEN (C+VEN) therapy after prior treatment with HMA+VE...

Full description

Bibliographic Details
Published in:eJHaem
Main Authors: Rafael Madero‐Marroquin, Joseph Cannova, Emily Dworkin, Austin Wesevich, Gregory W. Roloff, Caner Saygin, Mariam T. Nawas, Adam S. DuVall, Satyajit Kosuri, Michael J. Thirman, Olatoyosi Odenike, Wendy Stock, Richard A. Larson, Michael W. Drazer, Anand A. Patel
Format: Article
Language:English
Published: Wiley 2025-06-01
Subjects:
acute leukemia
AML
chemotherapy
MDS
myeloid leukemia
Online Access:https://doi.org/10.1002/jha2.70078
Description
Summary:ABSTRACT Background Outcomes for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that have progression after treatment with hypomethylating agent (HMA) and venetoclax (VEN) are poor. However, data for chemotherapy and VEN (C+VEN) therapy after prior treatment with HMA+VEN are limited. Methods We identified 18 patients with AML or MDS/AML who received C+VEN after prior HMA+VEN. Results Complete remission (CR) or CR with incomplete hematologic recovery (CRi) was achieved in 7 patients (39%) and 6 patients (33%) proceeded to allogeneic hematopoietic stem cell transplantation. Conclusion This study shows suggests that C+VEN could be a viable option in a subset of patients after HMA+VEN.
ISSN:2688-6146

Similar Items